The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Lee, J. M.; Spicer, J.; Nair, S.; Khattak, A.; Brown, M.; Meehan, R. S.; Shariati, N. M.; Deng, X.; Samkari, A.; Chaft, J. E. |
| Abstract Title: | The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406356 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS8116 |
| Notes: | Meeting Abstract: TPS8116 -- Source: Wos |
